Literature DB >> 23695883

Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1β, and NF-κB activators' expression in pristane-induced arthritis.

Max Brenner1, Teresina Laragione, Pércio S Gulko.   

Abstract

Cia4 is a locus on rat chromosome 7 that regulates disease severity and joint damage in models of rheumatoid arthritis, including pristane-induced arthritis (PIA). To identify molecular processes regulated by Cia4, synovial tissues from MHC-identical DA (severe erosive) and DA.F344(Cia4) congenics (mild nonerosive) rats were collected at preclinical and recent onset stages following the induction of PIA and analyzed for gene expression levels. Il6 levels were significantly higher in DA compared with congenics on day 10 (135-fold) after PIA induction (preclinical stage) and remained increased on days 14 (47.7-fold) and 18 (29.41-fold). Il6 increased before Il1b suggesting that Il6 could be driving Il1b expression and early synovial inflammation; 187 genes had significantly different expression levels and included inflammatory mediators increased in DA such Slpi (10.94-fold), Ccl7 (5.17-fold), and Litaf (2.09-fold). Syk or NF-κB activating and interacting genes, including Cd74 Ccl21, were increased in DA; 59 genes implicated in cancer-related phenotypes were increased in DA. Genes involved in cell metabolism, transport across membranes, and tissue protection such as Dgat1, Dhcr7, and Slc1a1 were increased in DA.F344(Cia4) congenics; 21 genes differentially expressed or expressed in only one of the strains were located within the Cia4 interval and could be the gene accounting for the arthritis effect. In conclusion, the Cia4 interval contains at least one new arthritis gene that regulates early Il6, Il1b expression, and other inflammatory mediators. This gene regulates the expression of cancer genes that could mediate the development of synovial hyperplasia and invasion, and cartilage and bone destruction.

Entities:  

Keywords:  autoimmunity; genetic prognosis; positional; rheumatoid

Mesh:

Substances:

Year:  2013        PMID: 23695883      PMCID: PMC3727023          DOI: 10.1152/physiolgenomics.00029.2013

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  46 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes.

Authors:  C Vingsbo; P Sahlstrand; J G Brun; R Jonsson; T Saxne; R Holmdahl
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

3.  Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium.

Authors:  G S Firestein; K Nguyen; K R Aupperle; M Yeo; D L Boyle; N J Zvaifler
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

4.  Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells.

Authors:  S Yamasaki; A Kawakami; T Nakashima; H Nakamura; M Kamachi; S Honda; Y Hirai; A Hida; H Ida; K Migita; Y Kawabe; T Koji; I Furuichi; T Aoyagi; K Eguchi
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

5.  A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats.

Authors:  E F Remmers; R E Longman; Y Du; A O'Hare; G W Cannon; M M Griffiths; R L Wilder
Journal:  Nat Genet       Date:  1996-09       Impact factor: 38.330

6.  Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation.

Authors:  A K Roshak; J R Jackson; K McGough; M Chabot-Fletcher; E Mochan; L A Marshall
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

7.  Induction of autoimmune arthritis in rats by immunization with homologous rat type II collagen is restricted to the RT1av1 haplotype.

Authors:  M M Griffiths; G W Cannon; P A Leonard; V R Reese
Journal:  Arthritis Rheum       Date:  1993-02

8.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

9.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

Authors:  Joel M Kremer; Rene Westhovens; Marc Leon; Eduardo Di Giorgio; Rieke Alten; Serge Steinfeld; Anthony Russell; Maxime Dougados; Paul Emery; Isaac F Nuamah; G Rhys Williams; Jean-Claude Becker; David T Hagerty; Larry W Moreland
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

Review 10.  Oncogenes in rheumatoid arthritis.

Authors:  U Müller-Ladner; J Kriegsmann; R E Gay; S Gay
Journal:  Rheum Dis Clin North Am       Date:  1995-08       Impact factor: 2.670

View more
  1 in total

1.  Commercial bovine proteoglycan is highly arthritogenic and can be used as an alternative antigen source for PGIA model.

Authors:  Larissa Lumi Watanabe Ishikawa; Priscila Maria Colavite; Larissa Camargo da Rosa; Bianca Balbino; Thais Graziela Donegá França; Sofia Fernanda Gonçalves Zorzella-Pezavento; Fernanda Chiuso-Minicucci; Alexandrina Sartori
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.